Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925557 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04925557 is a Phase 2 study that was terminated before completion, run by State University of New York at Buffalo. The registered enrollment target is 8 participants.
The verdict
NCT04925557, a Phase 2 study, was terminated before completion, sponsored by State University of New York at Buffalo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.
Interventions
- DRUG Mayzent
- DRUG Ocrevus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-11-13 |
| Est. Completion | 2023-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925557
The ClinicalTrials.gov registry entry for NCT04925557 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mayzent is the first listed.
NCT04925557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04925557 about?
NCT04925557 is a clinical study titled "Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis". To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chroni...
What is the current status of trial NCT04925557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2021-11-13. Estimated completion is 2023-08-05.
What interventions are being tested in trial NCT04925557?
The interventions under investigation include: Mayzent (DRUG), Ocrevus (DRUG).
Who is sponsoring clinical trial NCT04925557?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.